CRBU - Caribou Biosciences, Inc.
IEX Last Trade
1.655
0.020 1.208%
Share volume: 26,405
Last Updated: Fri 27 Dec 2024 08:30:06 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$1.64
0.02
1.22%
Fundamental analysis
9%
Profitability
0%
Dept financing
5%
Liquidity
75%
Performance
2%
Performance
5 Days
-5.03%
1 Month
-22.73%
3 Months
-14.14%
6 Months
1.19%
1 Year
-71.24%
2 Year
-69.96%
Key data
Stock price
$1.66
DAY RANGE
$1.61 - $1.73
52 WEEK RANGE
$1.60 - $8.33
52 WEEK CHANGE
-$70.33
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/05/2024
Company detail
CEO: Rachel E. Haurwitz
Region: US
Website: cariboubio.com
Employees: 100
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: cariboubio.com
Employees: 100
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Caribou Biosciences, Inc. engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010 and CB-011, which are in phase 1 clinical trials to treat relapsed or refractory B cell non-Hodgkin lymphoma.
Recent news